FPR2 Agonists for Ocular Inflammation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular inflammatory diseases often have significant side effects and limited efficacy, particularly in addressing excessive inflammatory responses in the eye.
Innovation Solution
Development of small molecule agonists specifically targeting Formyl peptide receptor 2 (FPR2), which exhibit potent anti-inflammatory activity and are suitable for ocular delivery, reducing side effects compared to broad-acting anti-inflammatories.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-acting anti-inflammatories (steroids or NSAIDs) are used to treat ocular inflammatory diseases, then anti-inflammatory efficacy is achieved, but side effects increase (elevated IOP and delays in wound healing)
Solution Approach 1:
The patent applies local quality by developing a targeted therapy that specifically activates FPR2 receptors in ocular tissues. The compound of formula (I) is designed to selectively bind to and activate FPR2, producing anti-inflammatory effects locally at the site of inflammation without the systemic side effects of broad-acting anti-inflammatories. This selective receptor targeting ensures that therapeutic action is concentrated where needed while sparing other physiological systems from adverse effects.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure to create a small molecule agonist with optimized properties for FPR2 activation. The molecular structure of formula (I) is specifically designed to achieve appropriate binding affinity and selectivity for FPR2, while also ensuring suitable pharmacokinetic properties for ocular delivery. This structural optimization allows the compound to effectively activate FPR2 signaling pathways without triggering off-target effects.
2Object-affected harmful factors
If FPR2 agonists are used to treat ocular inflammatory diseases, then side effects are reduced, but treatment specificity and potency must be optimized
Solution Approach 1:
The patent achieves local quality through selective FPR2 receptor targeting. The compound of formula (I) is designed with specific molecular features that enable selective binding to FPR2 receptors in ocular tissues. This selectivity ensures that anti-inflammatory effects are produced locally at the site of inflammation without affecting other physiological systems, thereby reducing side effects while maintaining treatment specificity.
Solution Approach 2:
The patent optimizes treatment specificity and potency through careful modification of molecular parameters. The structural parameters of compound (I) are adjusted to achieve optimal binding affinity for FPR2 while maintaining selectivity. The molecular structure is designed to fit the FPR2 binding pocket with appropriate geometric and electronic properties, ensuring potent and specific activation of the receptor without off-target effects.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.